REPL

Replimune Group (REPL)

About Replimune Group (REPL)

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Details

Daily high

$7.11

Daily low

$6.80

Price at open

$6.94

52 Week High

$13.24

52 Week Low

$2.68

Market cap

576.4M

Dividend yield

0.00%

Volume

180,169

Avg. volume

1.5M

P/E ratio

-1.95

Replimune Group News